Catalent, Inc. (CTLT)
Largest Insider Buys in Sector
CTLT Stock Price History Chart
CTLT Stock Performance
About Catalent, Inc.
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.
Insider Activity of Catalent, Inc.
Over the last 12 months, insiders at Catalent, Inc. have bought $0 and sold $1.57M worth of Catalent, Inc. stock.
On average, over the past 5 years, insiders at Catalent, Inc. have bought $671,930 and sold $327.18M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,000 shares for transaction amount of $49,980 was made by Ryan Michelle R (director) on 2023‑08‑31.
List of Insider Buy and Sell Transactions, Catalent, Inc.
| 2024-11-11 | Sale | director | 2,800 0.0015% | $59.70 | $167,160 | +3.08% | ||
| 2024-10-18 | Sale | SVP, General Counsel, CCO | 320 0.0002% | $59.97 | $19,190 | -0.18% | ||
| 2024-09-26 | Sale | Group President, Biologics | 1,994 0.0011% | $59.97 | $119,580 | +0.53% | ||
| 2024-08-02 | Sale | Group Pres. Pharma & Consumer | 1,169 0.0006% | $59.55 | $69,614 | +0.96% | ||
| 2024-08-02 | Sale | SVP, Quality & Reg. Affairs | 666 0.0004% | $59.55 | $39,660 | +0.96% | ||
| 2024-08-02 | Sale | SVP, Chief HR Officer | 3,859 0.0021% | $59.67 | $230,267 | +0.96% | ||
| 2024-08-02 | Sale | Pres. BioProduct Delivery, CoS | 662 0.0004% | $59.56 | $39,429 | +0.96% | ||
| 2024-08-02 | Sale | SVP, General Counsel, CCO | 608 0.0003% | $59.58 | $36,225 | +0.96% | ||
| 2024-07-29 | Sale | President & CEO | 9,088 0.005% | $58.76 | $534,011 | +1.92% | ||
| 2024-07-29 | Sale | Group Pres. Pharma & Consumer | 349 0.0002% | $58.70 | $20,486 | +1.92% | ||
| 2024-07-29 | Sale | SVP, Quality & Reg. Affairs | 283 0.0002% | $58.69 | $16,609 | +1.92% | ||
| 2024-07-29 | Sale | Pres. BioProduct Delivery, CoS | 206 0.0001% | $58.67 | $12,086 | +1.92% | ||
| 2024-07-08 | Sale | SVP, Chief Financial Officer | 2,993 0.0017% | $56.74 | $169,823 | 0.00% | ||
| 2024-06-04 | Sale | Pres. BioProduct Delivery, CoS | 1,401 0.0008% | $54.26 | $76,023 | +8.65% | ||
| 2024-03-15 | Sale | SVP, Quality & Reg. Affairs | 387 0.0002% | $56.20 | $21,749 | +4.21% | ||
| 2023-08-31 | director | 1,000 0.0006% | $49.98 | $49,980 | +9.95% | |||
| 2023-08-30 | Executive Chair | 21,000 0.012% | $50.24 | $1.06M | +12.17% | |||
| 2023-08-24 | Sale | Group Pres. Pharma & Consumer | 396 0.0002% | $44.49 | $17,618 | +22.22% | ||
| 2023-08-24 | Sale | President & CEO | 2,071 0.0011% | $44.54 | $92,245 | +22.22% | ||
| 2023-08-24 | Sale | EVP & Chief Admin Officer | 817 0.0004% | $44.65 | $36,479 | +22.22% |
Insider Historical Profitability
| Maselli Alessandro | President & CEO | 177521 0.0978% | $63.10 | 0 | 9 | |
| Gennadios Aristippos | Group Pres. Pharma & Consumer | 113724 0.0627% | $63.10 | 0 | 14 | |
| Gunther Scott | SVP, Quality & Reg. Affairs | 39635 0.0218% | $63.10 | 0 | 14 | |
| Evoli Lisa | SVP, Chief HR Officer | 39366 0.0217% | $63.10 | 0 | 1 | |
| McErlane David | Group President, Biologics | 36304 0.02% | $63.10 | 0 | 1 | |
| Masanovich Matti | SVP, Chief Financial Officer | 33871 0.0187% | $63.10 | 0 | 1 | |
| Hopson Ricky | Pres. BioProduct Delivery, CoS | 29974 0.0165% | $63.10 | 0 | 12 | |
| Ferraro Joseph Anthony | SVP, General Counsel, CCO | 23967 0.0132% | $63.10 | 0 | 2 | |
| Ryan Michelle R | director | 10835 0.006% | $63.10 | 1 | 1 | |
| Zippelius Peter | director | 4330462 2.3858% | $63.10 | 0 | 3 | |
| Chiminski John R | Executive Chair | 229888 0.1267% | $63.10 | 0 | 19 | |
| WALSH MATTHEW M | See Remarks | 93712 0.0516% | $63.10 | 0 | 6 | |
| Fasman Steven L | EVP & Chief Admin Officer | 73789 0.0407% | $63.10 | 0 | 15 | |
| Arnold Jonathan | SVP, CCO & Div. Head BioP Del. | 57399 0.0316% | $63.10 | 0 | 10 | |
| Joseph Wetteny | SVP & Chief Financial Officer | 49823 0.0274% | $63.10 | 0 | 3 | |
| MOREL DONALD E JR | director | 46958 0.0259% | $63.10 | 3 | 0 | +15.26% |
| Miyamoto Lance | SVP, Human Resources | 46799 0.0258% | $63.10 | 0 | 3 | |
| BUZY PETER L | President, Gene Therapy | 44500 0.0245% | $63.10 | 1 | 0 | +17.25% |
| Leonard Stephen | See Remarks | 44531 0.0245% | $63.10 | 0 | 2 | |
| Littlejohns Barry | President, Biologics & SDD | 37718 0.0208% | $63.10 | 0 | 2 | |
| Downie William | SVP, Global Sales & Marketing | 34926 0.0192% | $63.10 | 0 | 5 | |
| GREISCH JOHN J | Executive Chair | 34000 0.0187% | $63.10 | 2 | 0 | +20.08% |
| Flynn Karen | Chief Commercial Officer | 33223 0.0183% | $63.10 | 0 | 3 | |
| Pravda Ricardo | Chief Transformation Officer | 30224 0.0167% | $63.10 | 0 | 10 | |
| Grippo Michael J | SVP, Strategy & Corp. Dev. | 24449 0.0135% | $63.10 | 0 | 15 | |
| Kurt Nielsen | See Remarks | 23676 0.013% | $63.10 | 0 | 1 | |
| Houlton Scott | See Remarks | 23146 0.0128% | $63.10 | 0 | 3 | |
| Johnson Sharon | See Remarks | 22520 0.0124% | $63.10 | 0 | 3 | |
| Castellano Thomas P | SVP, Chief Financial Officer | 20099 0.0111% | $63.10 | 0 | 5 | |
| Dolan Christine | SVP - Product Development | 19449 0.0107% | $63.10 | 0 | 2 | |
| Schmidt Kay A | SVP, Enterprise Functions | 17388 0.0096% | $63.10 | 0 | 8 | |
| Roehrhoff Uwe | director | 16489 0.0091% | $63.10 | 1 | 0 | +6.41% |
| Boerman Manja | Pres. BioModalities Division | 14414 0.0079% | $63.10 | 0 | 3 | |
| Hunt Patricia | Pres. Consumer Health Div | 11289 0.0062% | $63.10 | 0 | 3 | |
| Lickfold Charles | SVP, CIO | 11339 0.0062% | $63.10 | 0 | 2 | |
| Carletti Lorenzo | SVP Global Ops Ph & Cons Hlth | 8746 0.0048% | $63.10 | 0 | 4 | |
| Hawkeswood Thomas W | Pres. Pharma Prod Delivery Div | 7533 0.0042% | $63.10 | 0 | 4 | |
| Riley Michael A. | Pres. Bio Product Delivery Div | 6592 0.0036% | $63.10 | 0 | 2 | |
| Gargiulo Mario | SVP, Ops, Biologics Europe | 5676 0.0031% | $63.10 | 0 | 4 | |
| Whitlow Ricci S | President, CSS | 2923 0.0016% | $63.10 | 0 | 3 | |
| LUCIER GREGORY T | director | 0 0% | $63.10 | 3 | 2 | +23.73% |
| Blackstone Management Associates V L.L.C. | 10 percent owner | 0 0% | $63.10 | 0 | 5 |
Institutional Investor Ownership
| The Vanguard Group | $1.15B | 11.28 | 20.41M | +1.08% | +$12.34M | 0.02 | |
| BlackRock | $857.85M | 8.4 | 15.2M | -6.05% | -$55.29M | 0.02 | |
| Capital World Investors | $729.58M | 7.14 | 12.92M | -32.26% | -$347.48M | 0.12 | |
| Nomura Holdings | $635.69M | 6.22 | 11.26M | -1.97% | -$12.77M | 5.55 | |
| Janus Henderson | $539.7M | 5.28 | 9.56M | -27.84% | -$208.22M | 0.27 | |
| State Street | $418.93M | 4.1 | 7.42M | -0.47% | -$1.96M | 0.02 | |
| Veritas Asset Management LLP | $340.13M | 3.33 | 6.03M | -6.84% | -$24.98M | 2.47 | |
| T. Rowe Price | $290.39M | 2.84 | 5.14M | -38.96% | -$185.33M | 0.04 | |
| Barclays | $269.04M | 2.63 | 4.77M | +27.99% | +$58.84M | 0.12 | |
| Geode Capital Management | $235.05M | 2.31 | 4.17M | +3.41% | +$7.74M | 0.02 | |
| T Rowe Price Investment Management Inc | $231.37M | 2.27 | 4.1M | -63.44% | -$401.4M | 0.14 | |
| Elliott Investment Management L P | $225.8M | 2.21 | 4M | 0% | +$0 | 2.37 | |
| Leonard Green & Partners | $218.24M | 2.14 | 3.87M | -10.97% | -$26.89M | 3.97 | |
| Hudson Bay Capital Management LP | $184.22M | 1.8 | 3.26M | +581.28% | +$157.18M | 1.23 | |
| Cadian Capital Management LP | $182.1M | 1.78 | 3.23M | -46.81% | -$160.24M | 6.48 | |
| Invesco | $177.37M | 1.74 | 3.14M | -17.77% | -$38.34M | 0.04 | |
| Alpine Associates Management Inc | $112.08M | 1.1 | 1.99M | New | +$112.08M | 0.29 | |
| Millennium Management LLC | $102.75M | 1.01 | 1.82M | +5,389.41% | +$100.88M | 0.07 | |
| Marshall Wace | $96.33M | 0.94 | 1.71M | +65.72% | +$38.2M | 0.1 | |
| BNY Mellon | $94.81M | 0.93 | 1.68M | -3.13% | -$3.06M | 0.02 | |
| Northern Trust | $92.91M | 0.91 | 1.65M | -19.98% | -$23.2M | 0.02 | |
| Charles Schwab | $91.01M | 0.89 | 1.61M | +3.31% | +$2.92M | 0.02 | |
| Capital International Investors | $82.86M | 0.81 | 1.47M | -50.98% | -$86.17M | 0.02 | |
| Morgan Stanley | $80.8M | 0.79 | 1.43M | -14.09% | -$13.25M | 0.01 | |
| Deutsche Bank | $74.43M | 0.73 | 1.32M | +47.58% | +$23.99M | 0.03 | |
| JPMorgan Chase | $66.93M | 0.66 | 1.19M | +38.25% | +$18.52M | 0.01 | |
| Dimensional Fund Advisors | $62.89M | 0.62 | 1.11M | -32.04% | -$29.65M | 0.02 | |
| Legal & General | $62.42M | 0.61 | 1.11M | -6.41% | -$4.28M | 0.01 | |
| UBS | $59.21M | 0.58 | 1.05M | +44.37% | +$18.2M | 0.02 | |
| Schroder Investment Management Group | $57.82M | 0.57 | 1.02M | -23.06% | -$17.33M | 0.07 | |
| Magnetar Capital | $56.43M | 0.55 | 999,628 | New | +$56.43M | 1.65 | |
| Westchester Capital Funds | $55.42M | 0.54 | 981,725 | New | +$55.42M | 0.52 | |
| AllianceBernstein | $54.48M | 0.53 | 965,060 | +364.78% | +$42.76M | 0.02 | |
| Balyasny Asset Management Llc | $52.18M | 0.51 | 924,417 | New | +$52.18M | 0.14 | |
| Fil Ltd | $50.97M | 0.5 | 903,000 | New | +$50.97M | 0.05 | |
| Nuveen | $47.27M | 0.46 | 837,435 | -4.34% | -$2.14M | 0.01 | |
| Assenagon Asset Management S.A. | $47.14M | 0.46 | 835,029 | +90.04% | +$22.33M | 0.12 | |
| Castle Hook Partners Lp | $46.93M | 0.46 | 831,437 | -19.03% | -$11.03M | 1.7 | |
| Adage Capital Partners Gp L L C | $46.7M | 0.46 | 827,300 | +202.96% | +$31.29M | 0.09 | |
| Goldman Sachs | $45.34M | 0.44 | 803,101 | -10.56% | -$5.35M | 0.01 | |
| Citigroup | $45.17M | 0.44 | 800,144 | -24.12% | -$14.36M | 0.03 | |
| TSW (Thompson, Siegel & Walmsley LLC) | $42.73M | 0.42 | 756,866 | -18.11% | -$9.45M | 0.66 | |
| Woodline Partners LP | $40.34M | 0.4 | 714,585 | New | +$40.34M | 0.34 | |
| The Manufacturers Life Insurance Company | $37.35M | 0.37 | 661,678 | -14.19% | -$6.18M | 0.03 | |
| Redmile Group | $35.7M | 0.35 | 632,464 | -42.53% | -$26.42M | 0.36 | |
| Bank of America | $33.26M | 0.33 | 589,269 | +3.83% | +$1.23M | <0.01 | |
| HSBC | $32.75M | 0.32 | 580,253 | +58.44% | +$12.08M | 0.02 | |
| Quinn Opportunity Partners Llc | $32.12M | 0.31 | 568,928 | New | +$32.12M | 2.45 | |
| Ubs Asset Management Americas Inc | $31.56M | 0.31 | 559,135 | -2.01% | -$647,650.83 | 0.01 | |
| Water Island Capital Llc | $30.76M | 0.3 | 544,860 | New | +$30.76M | 5.62 |